A recent study was carried out on an unselected, consecutive series of 306 patients from Canada with pancreatic ductal adenocarcinoma and mutations in BRCA2 were identified in 3.6% of the patients, with a total of 4.6% BRCA1/BRCA2 carriers identified [31], which does not differ significantly from our estimate for unselected Portuguese patients. Here, BRCA2 is linked to pancreatic ductal adenocarcinoma.